Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Mol Cell Oncol ; 3(1)2016 Jan 02.
Artículo en Inglés | MEDLINE | ID: mdl-26998512

RESUMEN

The involvement of Beclin 1 in cancer has been attributed primarily to its role in autophagy initiation. Our recent findings identify a novel, alternative mechanism by which Beclin 1 can impact tumor progression, through the regulation of growth factor receptor signaling.

2.
J Pharmacol Exp Ther ; 327(2): 316-23, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18708586

RESUMEN

The G protein-coupled serotonin 5-hydroxytryptamine (5-HT)(2A) receptor is primarily recognized for its role in brain neurotransmission, where it mediates a wide variety of functions, including certain aspects of cognition. However, there is significant expression of this receptor in peripheral tissues, where its importance is largely unknown. We have now discovered that activation of 5-HT(2A) receptors in primary aortic smooth muscle cells provides a previously unknown and extremely potent inhibition of tumor necrosis factor (TNF)-alpha-mediated inflammation. 5-HT(2A) receptor stimulation with the agonist (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(R)-DOI] rapidly inhibits a variety of TNF-alpha-mediated proinflammatory markers, including intracellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1), and interleukin (IL)-6 gene expression, nitric-oxide synthase activity, and nuclear translocation of nuclear factor kappaB, with IC(50) values of only 10 to 20 pM. It is significant that proinflammatory markers can also be inhibited by (R)-DOI hours after treatment with TNF-alpha. With the exception of a few natural toxins, no current drugs or small molecule therapeutics demonstrate a comparable potency for any physiological effect. TNF-alpha-mediated inflammatory pathways have been strongly implicated in a number of diseases, including atherosclerosis, rheumatoid arthritis, psoriasis, type II diabetes, depression, schizophrenia, and Alzheimer's disease. Our results indicate that activation of 5-HT(2A) receptors represents a novel, and extraordinarily potent, potential therapeutic avenue for the treatment of disorders involving TNF-alpha-mediated inflammation. Note that because (R)-DOI can significantly inhibit the effects of TNF-alpha many hours after the administration of TNF-alpha, potential therapies could be aimed not only at preventing inflammation but also treating inflammatory injury that has already occurred or is ongoing.


Asunto(s)
Antiinflamatorios/farmacología , Receptor de Serotonina 5-HT2A/fisiología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Transporte Activo de Núcleo Celular/efectos de los fármacos , Anfetaminas/farmacología , Animales , Relación Dosis-Respuesta a Droga , Molécula 1 de Adhesión Intercelular/genética , Interleucina-6/genética , Masculino , Óxido Nítrico Sintasa/antagonistas & inhibidores , Proteína Quinasa C/fisiología , Ratas , Ratas Sprague-Dawley , Agonistas del Receptor de Serotonina 5-HT2 , Factor de Transcripción ReIA/metabolismo , Molécula 1 de Adhesión Celular Vascular/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA